Bacterial Pneumonia Market Growth, Trends, and Forecast 2025 | Leading key players - Innoviva Inc., Pfizer Inc., Merck & Co., Inc.

The Global Bacterial Pneumonia Market reached US$ 2.7 billion in 2022 and is expected to reach US$ 5.0 billion by 2030 growing with a CAGR of 8.1% during the forecast period 2024-2031.

Bacterial Pneumonia Market report, published by DataM Intelligence, delivers detailed insights and analysis on major market trends, growth prospects, and emerging challenges. With a strong focus on providing actionable intelligence, DataM Intelligence enables businesses to make well-informed decisions and maintain a competitive edge. By blending both qualitative and quantitative research approaches, the company offers thorough reports that support clients in navigating complex market environments, driving strategic expansion, and capitalizing on new opportunities in today's rapidly evolving global landscape.

The Bacterial Pneumonia Market involves the diagnosis, treatment, and prevention of lung infections caused by bacteria, such as Streptococcus pneumoniae. It includes antibiotics, vaccines, and supportive care solutions. Rising infection rates, especially among the elderly and immunocompromised, along with growing antibiotic resistance, are key drivers influencing innovation and demand within this critical healthcare segment.

Request a Free Sample PDF of This Report (Corporate Email IDs Receive Priority Service): https://datamintelligence.com/download-sample/bacterial-pneumonia-market?sz

Market opportunities and Growth Drivers:

The Growing Number of Novel Product Launches Drive the Growth of the Bacterial Pneumonia Market

The bacterial pneumonia market is set to experience significant growth, driven by positive safety and efficacy outcomes in clinical trials that are paving the way for the launch of innovative new treatments.

For example, on March 14, 2022, Verity Pharmaceuticals International Ltd. and Cumberland Pharmaceuticals Inc. announced the launch of VIBATIV (telavancin) injectable in Puerto Rico. This breakthrough followed an agreement between the two companies, allowing Verity to bring the medication to patients in the region. VIBATIV is expected to be a game-changer for patients suffering from hospital-acquired or ventilator-associated pneumonia, including those caused by flu and COVID-19, offering the potential for life-saving treatment.

Bacterial Pneumonia Market Recent Development:

In July 2023, Merck released positive topline results from two Phase 3 studies on V116, an experimental 21-valent pneumococcal conjugate vaccine. The vaccine, if approved, would become the first pneumococcal conjugate vaccine specifically designed for adults. In the STRIDE-3 trial, adults who had never received a pneumococcal vaccine showed significant immune responses to V116 compared to PCV20 (20-valent pneumococcal conjugate vaccine), with notably improved serotype-specific opsonophagocytic activity (OPA) 30 days after vaccination.

In June 2023, Innoviva Inc. reported positive results from its Phase 3 program evaluating aztreonam-avibactam (ATM-AVI), a novel investigational antibiotic combination for severe Gram-negative bacterial infections. The ASSEMBLE and REVISIT studies found ATM-AVI to be safe, efficacious, and well-tolerated, with a safety profile comparable to aztreonam alone, showing promise as a treatment for infections caused by multi-drug resistant bacteria.

List of the Key Players in the Bacterial Pneumonia Market:

Innoviva Inc., Pfizer Inc., Merck & Co., Inc., Melinta Therapeutics LLC, Evopoint Biosciences, Aridis Pharmaceuticals Inc., Cumberland Pharmaceuticals Inc., Eagle Pharmaceuticals, Inc., Clarametyx Biosciences and Basilea Pharmaceutica Ltd among others.

Research Process:

Both primary and secondary data sources have been used in the global Bacterial Pneumonia Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/bacterial-pneumonia-market

Segment Covered in the Bacterial Pneumonia Market:

By Type: Community-Acquired Pneumonia (CAP), Hospital-Acquired Pneumonia (HAP).

By Route of Administration: Oral, Subcutaneous, Other.

By Treatments: Vaccines, Drugs.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis for Bacterial Pneumonia Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

People Also Ask:

Most Frequently Asked Questions in the Bacterial Pneumonia Market Research Industry:

âž  What are the global figures for sales, production, consumption, imports, and exports in the Bacterial Pneumonia market?

âž  Who are the top manufacturers in the global Bacterial Pneumonia industry, and what is their current status in terms of production capacity, output, sales performance, pricing structure, cost analysis, profit margins, and overall revenue?

âž  What key opportunities are available for vendors in the Bacterial Pneumonia market, and what challenges are they likely to encounter?

âž  Which application areas, end-user segments, or product types are projected to experience significant growth, and how is the market share distributed among them?

âž  What are the major drivers and barriers influencing the growth trajectory of the Bacterial Pneumonia market?

âž  What are the primary sales, marketing, and distribution strategies used across the global Bacterial Pneumonia industry landscape?

Browse More Reports: https://www.datamintelligence.com/research-report/bacterial-pneumonia-market

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.